Development and implementation of a strategy for intensified screening for gambiense human African trypanosomiasis in Kongo Central province, DRC.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
24
02
2020
accepted:
06
09
2020
revised:
27
10
2020
pubmed:
16
10
2020
medline:
9
2
2021
entrez:
15
10
2020
Statut:
epublish
Résumé
The Democratic Republic of the Congo (DRC) accounts for the majority of the reported gambiense human African trypanosomiasis (HAT) cases. Kongo Central province in the DRC reports a relatively low, yet steady number of cases, and forms a transboundary focus with Angola and the Republic of Congo. This paper describes an intervention aimed at reducing the case burden in Kongo Central by improving passive case detection, complemented with reactive screening. At the initiation of this programme in August 2015, 620 health facilities were identified and equipped with Rapid Diagnostic Tests (RDTs) for HAT screening. Of these, 603 (97%) reported use of RDTs, and 584 (94%) that continued to use RDTs to the last quarter of 2016 were used in the analysis going forward. Among all health facilities involved, 23 were equipped to confirm HAT by microscopy, and 4 of the latter were equipped to perform molecular testing with loop-mediated isothermal amplification (LAMP). Patients clinically suspected of HAT were tested with an RDT and those with a positive RDT result were referred to the nearest microscopy facility for confirmatory testing. If RDT positive patients were negative by microscopy, they were tested by LAMP, either on fresh blood or blood that was dried on filter paper and transported to a facility performing LAMP. This network of diagnostic facilities reduced the median distance for a patient to travel to a screening facility from 13.7km when the classical card agglutination test for trypanosomiasis (CATT) was used as a screening test in the past, to 3.4km. As a consequence, passive case detection was improved by between 30% and 130% compared to the period before. Furthermore, the proportion of HAT cases detected in early stage disease by passive screening increased from 27% to 64%. Reactive screening took place in 20 villages where cases were reported by passive screening, and in 45 villages in the neighbourhood of these villages. Reactive screening was responsible for detection of 40% of cases, of which, 90% were in first stage of the disease. This programme has demonstrated that it is possible to deploy passive screening for HAT at sub-country or country levels in the DRC, and this is made more effective when supplemented with reactive screening. Results and achievements showed an increase in the number of HAT cases detected, the majority of them in early disease, demonstrating that this strategy enables better population coverage and early detection of cases, which is critical in removing the HAT reservoir and interrupting transmission, and could contribute to HAT elimination in regions where it is implemented.
Sections du résumé
BACKGROUND
The Democratic Republic of the Congo (DRC) accounts for the majority of the reported gambiense human African trypanosomiasis (HAT) cases. Kongo Central province in the DRC reports a relatively low, yet steady number of cases, and forms a transboundary focus with Angola and the Republic of Congo. This paper describes an intervention aimed at reducing the case burden in Kongo Central by improving passive case detection, complemented with reactive screening.
METHODOLOGY/PRINCIPAL FINDINGS
At the initiation of this programme in August 2015, 620 health facilities were identified and equipped with Rapid Diagnostic Tests (RDTs) for HAT screening. Of these, 603 (97%) reported use of RDTs, and 584 (94%) that continued to use RDTs to the last quarter of 2016 were used in the analysis going forward. Among all health facilities involved, 23 were equipped to confirm HAT by microscopy, and 4 of the latter were equipped to perform molecular testing with loop-mediated isothermal amplification (LAMP). Patients clinically suspected of HAT were tested with an RDT and those with a positive RDT result were referred to the nearest microscopy facility for confirmatory testing. If RDT positive patients were negative by microscopy, they were tested by LAMP, either on fresh blood or blood that was dried on filter paper and transported to a facility performing LAMP. This network of diagnostic facilities reduced the median distance for a patient to travel to a screening facility from 13.7km when the classical card agglutination test for trypanosomiasis (CATT) was used as a screening test in the past, to 3.4km. As a consequence, passive case detection was improved by between 30% and 130% compared to the period before. Furthermore, the proportion of HAT cases detected in early stage disease by passive screening increased from 27% to 64%. Reactive screening took place in 20 villages where cases were reported by passive screening, and in 45 villages in the neighbourhood of these villages. Reactive screening was responsible for detection of 40% of cases, of which, 90% were in first stage of the disease.
CONCLUSIONS
This programme has demonstrated that it is possible to deploy passive screening for HAT at sub-country or country levels in the DRC, and this is made more effective when supplemented with reactive screening. Results and achievements showed an increase in the number of HAT cases detected, the majority of them in early disease, demonstrating that this strategy enables better population coverage and early detection of cases, which is critical in removing the HAT reservoir and interrupting transmission, and could contribute to HAT elimination in regions where it is implemented.
Identifiants
pubmed: 33057341
doi: 10.1371/journal.pntd.0008779
pii: PNTD-D-20-00147
pmc: PMC7591064
doi:
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0008779Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist. FIND is not a funding agency, but a non-profit organization that is funded by multiple donors.
Références
Emerg Infect Dis. 2005 Sep;11(9):1382-8
pubmed: 16229766
Lancet Glob Health. 2014 Jun;2(6):e359-63
pubmed: 25103304
PLoS Negl Trop Dis. 2018 Mar 28;12(3):e0006386
pubmed: 29590116
PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2504
pubmed: 24147176
PLoS One. 2017 Oct 12;12(10):e0186429
pubmed: 29023573
Trop Med Infect Dis. 2020 Apr 04;5(2):
pubmed: 32260405
PLoS Negl Trop Dis. 2012;6(11):e1919
pubmed: 23209860
Epidemics. 2017 Mar;18:101-112
pubmed: 28279451
PLoS Negl Trop Dis. 2012 Jan;6(1):e1467
pubmed: 22272367
Parasit Vectors. 2015 Oct 22;8:532
pubmed: 26490248
PLoS Negl Trop Dis. 2012;6(10):e1859
pubmed: 23145192
PLoS One. 2012;7(2):e31743
pubmed: 22363717
PLoS Negl Trop Dis. 2016 Apr 08;10(4):e0004608
pubmed: 27058033
Acta Trop. 2012 Feb;121(2):135-40
pubmed: 22079374
Int J Health Geogr. 2015 Jun 06;14:20
pubmed: 26047813
PLoS One. 2017 Jul 3;12(7):e0180555
pubmed: 28672036
PLoS Negl Trop Dis. 2015 Mar 13;9(3):e0003578
pubmed: 25769046
PLoS One. 2018 Sep 21;13(9):e0204335
pubmed: 30240406